Trial Profile
An Open-Label, Multiple Centers, Non-randomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Gastric cancer; Liver cancer; Lung cancer; Nasopharyngeal cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 Apr 2020 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Planned End Date changed from 1 Apr 2017 to 1 Dec 2019.
- 17 Dec 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2019.